Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

ence and severity of adverse events (AEs) were comparable for both treatment groups and were consistent with prior experience with Synagis. There were comparable rates of related AEs and drug discontinuations between treatment groups [related AEs: motavizumab (N=298, 9.0 percent) vs. Synagis (N=258, 7.8 percent) p=not significant (NS); discontinuations: motavizumab (N=13, 0.4 percent) vs. Synagis (N=10, 0.3 percent) p=NS]. AEs related to skin hypersensitivity reactions resulted in discontinuation of dosing in motavizumab-treated patients at low frequency (N=9, 0.3 percent). In Synagis-treated patients, there were no AEs consistent with skin hypersensitivity reactions that resulted in dosing discontinuation. The overall mortality rates were not statistically different between the two groups (N=8, 0.2 percent motavizumab and N=4, 0.1 percent Synagis); no death was considered to be related to the study drugs and there were no RSV-related deaths. Immunogenicity in the motavizumab arm was less than 1 percent and comparable to the historical Synagis rate.

The trial was a randomized, double-blind study involving 6,635 high-risk infants at 347 centers in 24 countries through three RSV seasons. Study participants comprised premature infants born at 35 weeks gestational age or less who were six months of age or younger at randomization, as well as children with CLD related to prematurity requiring medical management within the six months prior to study entry, who were 24 months of age or less at randomization.

About RSV

Each year, an estimated 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second bir
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
(Date:2/27/2015)... --  Synageva BioPharma Corp. (Synageva) (NASDAQ: ... products for rare diseases, joins the National Organization ... Rare Diseases™ (EURORDIS™), The Global Genes Project™, and ... Day. On the last day of ... participants conduct special events to raise awareness and ...
(Date:2/27/2015)... 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... announced financial results for its first quarter ended December ... ended December 31, 2014, revenue was $1,336,685. Operating expenses ... or $0.02 per share.  Covalon,s President ... very pleased with the significant progress we have made ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... Reportlinker.com announces that a new market research ... Macular Degeneration Therapy Area Pipeline Report ... Macular Degeneration Therapy Area Pipeline Report contains detailed ... report provides insight into the pipeline status of ...
... April 13, 2011 Allscripts (NASDAQ: MDRX ) ... the three months ended March 31, 2011 after the stock ... host a conference call and webcast to discuss the company,s ... on the same day. (Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO ) ...
Cached Medicine Technology:Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 2Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 2Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 4
(Date:2/27/2015)... Daytona Beach, FL (PRWEB) February 27, 2015 ... marketing medical companies, devices and pharmaceuticals, Benedict Advertising ... FL as its newest client. The company’s patented ... is a pain-free, no-stress method of sedation. , ... taking medical patient comfort to a new level, ...
(Date:2/27/2015)... NY (PRWEB) February 27, 2015 The winter ... mold growth and expansion. When mold grows, it can be ... be sure to avoid the consequences of mold growth with ... Long Island, is offering tips on the best ways to ... wet season, which makes perfect conditions for mold to thrive. ...
(Date:2/27/2015)... Vancouver, BC (PRWEB) February 27, 2015 ... exciting overnight deals for couples who wanted to spend ... with the opportunity to get a jump on Valentine’s ... meal and stay in one of their luxurious rooms. ... on February 13, inviting guests for a mouthwatering 3 ...
(Date:2/27/2015)... Florida Hospital North Pinellas is being recognized ... Plus hospital. In order to receive the award, Florida ... all Get With The Guidelines - Stroke Quality Achievement ... achieved 75-percent or higher compliance with six of 10 ... are reporting initiatives to measure quality of care. ...
(Date:2/27/2015)... The UC Davis Huntington’s Disease Center, whose ... a beacon of hope for people with Huntington’s disease ... the national society committed to the values that it ... America — as a Level 1 Huntington’s Disease Center ... service to over 300 families coping with Huntington's disease ...
Breaking Medicine News(10 mins):Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:Enviro-Test Offers Tips for Winter Mold Prevention 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2Health News:Florida Hospital North Pinellas Receives Get With The Guidelines - Stroke Gold Plus Quality Achievement Award 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 3
... ... and other patient safety information in the public eye , ... San Francisco vary dramatically in terms of how well their ... disability, and expense in our nations, hospitals that is largely preventable.  On ...
... ... patient safety information in the public eye , YONKERS, N.Y. ... Dallas/Fort Worth area vary dramatically in terms of how well their ... disability, and expense in our nations, hospitals that is largely preventable.  On ...
... , Feb. 2 It,s all smiles in Waterbury ... Wolcott Street, Waterbury, CT in the Fair Oaks Shopping Center. ... January 22nd, 2010 in a mission to expand access to ...  Senator J. Hartley and State Representative Selim Noujaim joined the ...
... ... at CoastToCoastMattress.com. Featuring star name brands like Sealy Posturepedic, Simmons Beautyrest and Tempur-Pedic, the ... , ... 2010 -- Coast To Coast Mattress is proud to announce its new mattress lineup, ...
... , ... partnership with SLI-Systems brings advanced Learning Search & Navigation to online health & beauty ... (PRWEB) ... functionality across the Medichest.com platform. , , , , ,Learning Search tracks and ...
... ... the new Wella SP range is set to raise the bar within the hair ... Newport Pagnell, ... world, Wella is at the forefront of hairdressing innovation. The introduction of New SP personalised ...
Cached Medicine News:Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 2Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 3Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 4Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 5Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 6Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 7Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 2Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 3Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 4Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 5Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 6Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 7Health News:Senator J. Hartley and Representatives Noujaim and Berger Celebrate Kool Smiles Opening in Waterbury 2Health News:Senator J. Hartley and Representatives Noujaim and Berger Celebrate Kool Smiles Opening in Waterbury 3Health News:Coast To Coast Mattress Announces Its New Mattress Lineup 2Health News:Medichest Launches Learning Search 2
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Severe revision options for the knee and hip...
Medicine Products: